Skip to main content

Quadrivalent Meningococcal Conjugate Vaccine

Award type :
Product Development Award
Product type :
Vaccines
Award year :
2020
Project start date :
04 / 29 / 2020
Project end date :
12 / 31 / 2023
Project duration (months) :
36
Development stage :
Phase 1, Phase 2, Phase 3
Target disease :
Meningitis
Region served :
Low- and Middle-Income Countries
Recipient organization / Country of funding recipient organization :
EuBiologics / Republic of Korea
Collaborator(s) / Country :
-
Funding amount(KRW) :
4,000,000,000

Currently available meningococcal conjugate vaccines have numerous drawbacks such as narrow protection range, high prices, or inappropriate formulations (for instance, lyophilized vaccine). EuBiologics is developing a tetravalent meningococcal conjugate vaccine with serogroups A, C, W-135, and Y conjugated to recombinant CRM 197 in a liquid formulation. This vaccine will be a significant step in the advancement of an affordable and easily available multivalent meningococcal conjugate vaccine for low- and middle-income countries, and supports the Defeating Meningitis by the 2030 initiative of the World Health Organization (WHO). The scope of work includes evaluating safety, tolerability, and immunogenicity in healthy Korean adults and benchmarking against competitor vaccines.